次黃嘌呤-鳥嘌呤磷酸核苷轉移酶

次黃嘌呤-鳥嘌呤磷酸核苷轉移酶(Hypoxanthine-guanine phosphoribosyltransferase,簡稱HGPRT)為人體內一個轉譯自HPRT1基因酵素[1][2]

次黃嘌呤-鳥嘌呤磷酸核苷轉移酶
識別號
别名;HPRTinosinic pyrophosphorylaseinosinate pyrophosphorylaseinosinic acid pyrophosphorylaseinosine 5'-phosphate pyrophosphorylaseIMP:diphosphate phospho-D-ribosyltransferaseHGPRTaseIMP diphosphorylaseIMP pyrophosphorylaseIMP-GMP pyrophosphorylase
外部IDGeneCards
直系同源
物種人類小鼠
Entrez

无数据

无数据

Ensembl

无数据

无数据

UniProt

无数据

无数据

mRNA序列

无数据

无数据

蛋白序列

无数据

无数据

基因位置(UCSC)无数据无数据
PubMed查找无数据无数据
維基數據

HGPRT為一種轉移酶,可以催化將次黃嘌呤轉換為肌苷酸(IMP),也可將鳥嘌呤的反應轉為單磷酸鳥苷。這兩個反應都是將PRPP的5-磷酸核苷轉移至嘌呤上。HGPRT在核苷酸再利用合成途徑中扮演重要角色。

功能

hypoxanthine phosphoribosyltransferase
识别码
EC編號 2.4.2.8
CAS号 9016-12-0
数据库
IntEnz IntEnz浏览
BRENDA BRENDA入口
ExPASy NiceZyme浏览
KEGG KEGG入口
MetaCyc 代谢路径
PRIAM 概述
PDB RCSB PDB PDBj PDBe PDBsum
基因本体 AmiGO / EGO

HGPRT催化下列反應:

反應物產物備註
次黃嘌呤肌苷酸
鳥嘌呤單磷酸鳥苷常稱HGPRT,僅有部分物種有此功能。
黄嘌呤單磷酸黃核苷特定HPRT

HGPRTase functions primarily to salvage purines from degraded DNA to reintroduce into purine synthetic pathways. In this role, it catalyzes the reaction between guanine and phosphoribosyl pyrophosphate (PRPP) to form GMP, or between hypoxanthine and phosphoribosyl pyrophosphate (PRPP) to form inosine monophosphate.

Substrates and inhibitors

Comparative homology modelling of this enzyme in L. donovani suggest that among all of the computationally screened compounds, pentamidine, 1,3-dinitroadamantane, acyclovir and analogs of acyclovir had higher binding affinities than the real substrate (guanosine monophosphate).[3]

疾病中的角色

此基因的突變往往導致高尿酸血症

  • 一些男性帶有部分程度的HGPRT缺陷(約低於正常活動量20%)並因此導致血液中高濃度的尿酸。隨之而來的是痛風以及腎結石。這症狀稱為凱利-塞米勒症候群[4]
  • 萊希-尼亨症候群起源由HPRT1突變導致的HGPRT缺陷。[5]
  • 某些基因突變可能導致痛風。發病的風險與hypoxanthine-guanine phosphoribosyltransferase的缺陷程度成正比。
  • HPRT expression on the mRNA and protein level is induced by hypoxia inducible factor 1 (HIF1A). HIF-1 is a transcription factor that directs an array of cellular responses that are used for adaptation during oxygen deprivation. This finding implies that HPRT is a critical pathway that helps preserve the cell's purine nucleotide resources under hypoxic conditions as found in pathology such as myocardial ischemia.[6]

The in silico and in-vitro correlation of these compounds were test in Leishmania HGPRT and validates the result.[7]

Hybridomas

Hybridomas are immortal (immune to cellular senescence), HGPRT+ cells that result from fusion of mortal, HGPRT+ plasma cells and immortal, HGPRT myeloma cells. They are created to produce monoclonal antibodies in biotechnology. HAT medium inhibits de novo synthesis of nucleic acids, killing myeloma cells that cannot switch over to the salvage pathway, due to lack of HRPT1. The plasma cells in the culture eventually die from senesence, leaving pure hybridoma cells.

參考文獻

  1. .
  2. Finette BA, Kendall H, Vacek PM. . Mutation Research. Aug 2002, 505 (1-2): 27–41. PMID 12175903. doi:10.1016/S0027-5107(02)00119-7.
  3. Ansari MY, Dikhit MR, Sahoo GC, Das P. . International Journal of Biological Macromolecules. Apr 2012, 50 (3): 637–49. PMID 22327112. doi:10.1016/j.ijbiomac.2012.01.010.
  4. Khattak FH, Morris IM, Harris K. . British Journal of Rheumatology. May 1998, 37 (5): 580–1. PMID 9651092. doi:10.1093/rheumatology/37.5.580c.
  5. Hladnik U, Nyhan WL, Bertelli M. . Archives of Neurology. Sep 2008, 65 (9): 1240–3. PMID 18779430. doi:10.1001/archneur.65.9.1240.
  6. Wu J, Bond C, Chen P, Chen M, Li Y, Shohet RV, Wright G. . Journal of Molecular and Cellular Cardiology. Feb 2015, 82: 194–200. PMID 25681585. doi:10.1016/j.yjmcc.2015.01.014.
  7. Ansari MY, Equbal A, Dikhit MR, Mansuri R, Rana S, Ali V, Sahoo GC, Das P. . International Journal of Biological Macromolecules. Nov 2015, 83: 78–96. PMID 26616453. doi:10.1016/j.ijbiomac.2015.11.051.

延伸閱讀

外部連結

Category:EC 2.4.2

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.